Table III.

Multivariate analysis of clinical outcome adjusting for treatment (TT2 + THAL, TT2 − THAL, TT 1).

		Overall survival		Event-free survival		CR duration
Cytogenetic abnormality	262/848 (31%)	1.84 (1.50, 2.25)	<0.001	1.48 (1.24, 1.78)	<0.001	112/433 (26%)	1.51 (1.14, 2.01)	0.005
Creatinine ≥176.8 μmol/l	79/848 (9%)	1.72 (1.28, 2.31)	<0.001	NS2	NS2	–	NS2	NS2
Enrolled in TT1	214/848 (25%)	1.49 (1.20, 1.86)	<0.001	1.75 (1.46, 2.11)	<0.001	92/433 (21%)	2.04 (1.53, 2.72)	<0.001
LDH ≥190 U/l	243/848 (29%)	1.42 (1.14, 1.77)	0.002	1.41 (1.17, 1.70)	<0.001	–	NS2	NS2
Age ≥65 years	147/848 (17%)	1.33 (1.03, 1.71)	0.030	NS2	NS2	–	NS2	NS2
CRP ≥8 mg/l	326/848 (38%)	1.25 (1.02, 1.54)	0.031	NS2	NS2	–	NS2	NS2
B2M ≥3.5 mg/l	320/848 (38%)	NS2	NS2	1.44 (1.21, 1.72)	<0.001	153/433 (35%)	1.41 (1.08, 1.86)	0.013

Results given as Hazard Ratio (95% confidence intervals), P-value from Wald chi-square test in Cox regression.

NS2 – Multivariate results not statistically significant at 0.05 level.

Multivariate model uses stepwise selection with entry level 0.1 and variable remains if it meets the 0.05 level.

Other variables considered for OS and EFS: Hb and CRP; for CR duration: Hb, IgA and LDH.